SCHEMBL5454714

SCHEMBL5454714

Nc1nccc(-c2c(-c3ccc(F)cc3)nn3c(NC4CCCC4)cccc23)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 11/20 0.47
CSNK1D P48730 3/20 0.47
MAPK13 O15264 2/20 0.47
MAPK12 P53778 2/20 0.47
MAPK11 Q15759 2/20 0.47
EGFR P00533 1/20 0.47
CSNK1E P49674 1/20 0.47
KCNH2 Q12809 1/20 0.47
RIPK2 O43353 1/20 0.41
DYRK3 O43781 1/20 0.41
PRKD3 O94806 1/20 0.41
MAP4K4 O95819 1/20 0.41
PRKCG P05129 1/20 0.41
LCK P06239 1/20 0.41
LYN P07948 1/20 0.41
RET P07949 1/20 0.41
PIM1 P11309 1/20 0.41
PRKACA P17612 1/20 0.41
MAPK1 P28482 1/20 0.41
FLT4 P35916 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5456838 0.90 CSNK1D (0.51) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL5462491 0.89 CSNK1D (0.51) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL5455358 0.87 MAPK14 (0.42) MAPK14CSNK1DGSK3B
SCHEMBL6184465 0.86 GSK3B (0.55) MAPK14CSNK1DGSK3B
SCHEMBL6108947 0.86 TP53 (0.45) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL6183945 0.85 GSK3B (0.61) MAPK14MAPK13MAPK12MAPK11GSK3B
SCHEMBL5452916 0.83 CSNK1D (0.51) MAPK14CSNK1DMAPK13MAPK12MAPK11
SCHEMBL5453385 0.82 MAPK14 (0.51) MAPK14
SCHEMBL5457302 0.82 MAPK14 (0.50) MAPK14CSNK1DEGFRKDRMAPK9
SCHEMBL6106593 0.81 TP53 (0.46) MAPK14CSNK1DMAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1377573-B1 PYRAZOLOPYRIDINE DERIVATIVES GLAXO GROUP LTD (GB) 2005-07-27 EP claimed
US-20070287721-A1 Pyrazolopyridinyl pyridine BOYD F LESLIE 2007-12-13 US disclosed
US-20070287721-A1 Pyrazolopyridinyl pyridine BOYD F LESLIE 2007-12-13 US disclosed
US-20070287721-A1 Pyrazolopyridinyl pyridine BOYD F LESLIE 2007-12-13 US disclosed
US-7163940-B2 Pyrazolopyridinyl pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2007-01-16 US disclosed
US-7163940-B2 Pyrazolopyridinyl pyrimidine therapeutic compounds SMITHKLINE BEECHAM CORPORATION (US) 2007-01-16 US disclosed
EP-1377573-B1 PYRAZOLOPYRIDINE DERIVATIVES GLAXO GROUP LTD (GB) 2005-07-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070287721-A1 Pyrazolopyridinyl pyridine CYP3A5, CYP2C19, CYP3A4 MAPK14 2533/4885CSNK1D 411/4885MAPK13 1668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.